May 15th In NYC: CannaStocks2019 Q1 Investor Conference

CaptureCannaStocks2019 Q1 Investor Conference takes place today (May 15, 2019) in New York City. 

For Investment Professionals, Accredited Investors, and Financial Media

8AM-6PM – Reservations required. Send an INQUIRY to bruce@cannastocks2019.com

OTC Markets Group, 300 Vesey Street, NYC 10282

Featuring: Presentations, Q-and-A, and Panels with select OTC Markets Group leaders in the Cannabis sector. Themes to be explored: innovation, consolidation, international expansion, specialization, legalities, and advertising. 

Companies presenting: KushCo Holdings, Acreage Holdings, MariMed, Emerald Bioscience, OrganiGram Holdings, Sproutly, Emerald Health Therapeutics, Supreme Cannabis Company, Canopy Rivers, 1933 Industries, AXIM Biotechnologies, GSRX Industries, and New Frontier Data will provide an industry overview about current market trends. Investors unable to attend can watch a video webcast of the conference.


To pre-register for the webcast, click HERE:
https://protect-us.mimecast.com/s/_tFRCmZEyPCjvvoruG4-KO?domain=tinyurl.com

There is no charge for access to the webcast. Those unable to view the webcast on May 15 will find it archived and for later viewing on the Virtual Investor Conferences website.

OrganiGram Announces Voluntary Product Recall

CANADA: Licensed medical marijuana producer Organigram Holdings has announced it is voluntarily recalling certain lots of medical marijuana which were supplied between August and December 2016 due to the detection of amounts of an unapproved pesticide not registered for use on marijuana under the Pest Control Products Act.

Following discussions with Health Canada, this has been deemed a Type III recall, which is defined as “a situation in which the use of, or exposure to, dried marijuana, fresh marijuana or cannabis oil, marijuana plants or seeds is not likely to cause any adverse health consequences.” The source of the substance is unknown as Organigram is a certified organic grower and does not use compounds of this nature in its production processes. The Company is cooperating with Health Canada officials to determine how the substance came into contact with the marijuana.

Organigram’s client service department is directly notifying all clients affected by the recall. Any further action, if necessary, will be undertaken at the direction of Health Canada. Currently the number of lots affected is small, however, additional screening could result in additional lots being determined to be compromised. In the event that the number of contaminated lots significantly increases, the Company’s operating revenue could be negatively affected.